Lipocine Inc.(LPCN)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Lipocine Inc. (LPCN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LPCN at 6.1/100 on a 32-signal composite quality model, placing it at rank #2,952 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Lipocine Inc. reports quarterly revenue of $190.1K, net income of $-2.6M. Top institutional holders of LPCN by reported 13-F value include Squadron Capital Management, Ikarian Capital, Eversept Partners, based on the most recent SEC filings. LPCN trades on the Nasdaq exchange and files with the SEC under CIK 1535955. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LPCN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lipocine Inc. directly from SEC EDGAR.